Mytoximonotatist enters clinical use phase at Shanghai Spike Hospital
-
Last Update: 2020-07-07
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
China's first single anti-drug drug for the treatment of primary liver cancer with independent intellectual property rights, metoxiate, was recently put into clinical use in two medical institutions in Shanghai and Guangzhou for the treatment of advanced primary liver cancerThe PLA 458hospitalhas admitted 30 patients to try metorifitoAt present,hospitalfollow-up observation of patients who have formally used the drug to treat patients found that the early stage of the therapy can see the improvement of symptoms of patients, such as pain relief, fever and body temperature gradually normalIt is understood that the medical community will also be the scope of the application of the utoxil monotomatox in-depth, forward-looking researchStudies have shown that the specific binding of the drug to liver cancer cells has a specific killing mechanism, the same therapeutic effect on liver cancer cells in various stages, in the future will do in-depth study of these areas, to understand its early liver cancer, subclinical liver cancer application program, efficacy assessment and the drug on anti-metastasis, anti-recurrence role(Zongqun)
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
